New Industries Require New Insight

The microbiome and its role in human health represents a paradigm shift in how medicines will be developed. The PRI was founded to make Microbiotic Medicinal Products a therapeutic reality in Europe.

Learn More

A Unique Collaborative Approach

The PRI, as a neutral and financially independent non-profit association, applies a unique collaborative approach to improve market access and provide technical and regulatory intelligence for its members.

Our Strategy

The Future of Human Health

The PRI believes that the microbiome is the future of human medicine. Our members have a stake in regulatory, technical and collaboration efforts of the microbiome & human health space.

Our Members

Board of Directors

President

Bruno Pot

Yakult Europe

First Vice President

Sandrine Claus

YSOPIA Bioscience

Second Vice President

Charlotte Hemmingsen

Chr. Hansen

Secretary

Frédérique Vieville

5QBD Biotech

Treasurer

Stanislas Desjonquères

Nexbiome Therapeutics

Board Member

Jelena Cvejic

Accelsiors CRO

Ana Enriquez

ADM Protexin

Nail Nasir

Astel Medica

Vincent Thomas

Bioaster

Gianfranco Grompone

BioGaia AB

Luc Sterkman

Caelus Health

Michelle Carr

Ferring Pharmaceuticals

Board of Directors

Katarina Lundh

Johnson & Johnson

Éile Butler

Labskin UK

Sylvie Binda

Lallemand Health Solutions

Eugenio Fernandez

MaaT Pharma

Selin Bolca

MRM Health

Sin-Hyeog Im

POSTECH

Marco Pane

Probiotical

Grégory Lambert

TargEDys

Monique Alric

University Clermont-Auvergne (UCA)

Laurent Rios

VetAgro Sup

Ingmar Claes

YUN Probiotherapy

Meet the Team

Magali

Scientific & Regulatory Affairs Director

Céline

Microbiome Project Manager

Joseph

Operations Manager

Nick

Pharmabiotics Event Director

Our Members

Start Ups

Biotechs

Investors

CROs

Research Institutions

LBP Developers

CDMOs

Pharma

Our current Members

Membership in the PRI plays an important role in several of our members’ development & marketing strategies.

Intelligence

Development Planning

Networking

Scientific Foresight

Investment

Membership Packages

What are Microbiotic Medicinal Products (MMPs)?

The PRI defines MMPs as any medicinal product containing living, dead or fragments…, of components of the microbiome (i.e. bacteria, yeasts, phages, etc…) with the purpose to prevent or treat human diseases through a pharmacological, microbiological, neurological, immunological or metabolic mode of action, or make a medical diagnosis.

Non-Living Cells

Live Biotherapeutic Products

Faeces-derived Rx

Phage Therapy

Non-profit Association (loi 1901) | Europe’s first Microbiome Regulatory Science Expertise Center whose mission is to clarify and confirm the specific requirements for the development of microbiome-based medicinal products.

FIND OUT MORE

Expertise

Patients/Health

Medicine

Synergy

Find out more about the PRI from some of her members…

Bruno Pot

Peter Cartwright

Stanislas Desjonquères

Nina Vinot

“…I am deeply convinced that if we grow our microbiotic medicinal products business, all companies and universities and academics should gather to create a new kind of offer to better treat patients.” Stanislas Desjonquères

“We had been thinking for sometime that the regulatory structure of probiotics was not satisfactory – probiotics had evolved from fermented foods – but really it fits more comfortably in the medicinal sector.” Peter Cartwright

“…for a Pharma company like Ferring, we really understand and think that next step will be developing Pharmabiotics in a true ‘Pharma’ way, and the PRI is in our opinion is the key partner and leader in Europe.” Jaimé Lopez

Magali Cordaillat-Simmons

Marco Pané

“The possibility to link up the academic world as well as the industry world in the PRI is really a very interesting option.” Bruno Pot

“…I’m really glad to be a part of these Task Groups – at the moment the PRI activities indeed for our company is something really relevant.” Marco Pané

Etienne Nouguez

“Probiotical has been with the PRI since the very beginning – and we’re very happy about our investment, as it is more and more important for developing Live Biotherapeutic Products.” Nina Vinot

“We are interested in the way the PRI is working with industrials, academics and Regulatory bodies to construct this market for pharmabiotics.” Etienne Nouguez

“…in fact the European aspect grew and grew for the PRI…an association that began with French roots has now become a truly European organization.” Massimo Marzorati